PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) announced that its subsidiary BioGene Therapeutics Inc. appointed Dr. Francis Tavares as Chief Technology Officer effective August 19, 2025.

Dr. Tavares previously served as President, CEO, and Founder of ChemoGenics BioPharma, where he led drug discovery initiatives. He also worked as Group Manager in the Medicinal Chemistry Division at GlaxoSmithKline, receiving the Excellence in Science Award in 2004.

He holds a PhD in Organic Chemistry from Colorado State University and completed postdoctoral research at the University of Texas at Austin. His work has focused on developing small-molecule inhibitors for kinases, proteases, and nuclear receptors, contributing to the commercialization of Trilaciclib and the completion of Phase 3 clinical trials of Lerociclib.

"We are thrilled to welcome Dr. Tavares to the executive team of BioGene Therapeutics," said Stephen Van Deventer, Chairman and CEO of BioGene Therapeutics Inc. "His thirty years of experience in drug discovery, organic and medical chemistry, paired with his proven track record of turning scientific innovation into successful products, will make him an invaluable part of our company's team."

BioGene Therapeutics is a Texas-based life sciences company focused on metabolic health and gene-based treatments. The company operates a subsidiary in Australia to access the country's 43.5% R&D tax cashback incentive while conducting research on gene therapy approaches for diabetes and obesity.

PreveCeutical develops preventive and curative therapies using organic and nature-identical products, with research programs including dual gene therapy for diabetes and obesity, and nonaddictive analgesic peptides.